Figures
Figure 1. Association of LINC01121 expression with clinicopathologic characteristics: (a) expression level of LINC01121 in CRC samples and normal tissues; (b) LINC01121 expression in T1-2 stage patients compared to T3-4 stage; (c) LINC01121 expression in lymphatic metastasis-positive patients compared to those without lymphatic metastasis; (d) LINC01121 expression in M0 stage compared to M1 stage; (e) expression of LINC01121 in TNM stage I-II compared to III-IV; (f) ROC curve of LINC01121. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. CRC: colorectal cancer; ns: not significant; ROC: receiver operating characteristic.
Figure 2. Kaplan-Meier survival curves comparing the high and low expression of LINC01121 in CRC patients: (a) overall survival; (b) progression-free interval; (c) disease-specific survival; (d-f) overall survival analyses of T2-T4, N1-2, and stages III and IV subgroup. CRC: colorectal cancer.
Figure 3. Quantitative methods to predict probability of 1-, 3-, 5-year OS, DSS, and PFI of CRC patients. Nomogram for predicting the probability of 1-, 3-, 5-year OS (a), DSS (c), and PFI (e) for CRC patients. Calibration plots of the nomogram for predicting the probability of OS (b), DSS (d), and PFI (f) at 1, 3, and 5 years. CRC: colorectal cancer; DSS: disease-specific survival; OS: overall survival; PFI: progression-free interval.
Figure 4. Enrichment analysis of LINC01121 in CRC: (a) proliferation; (b) NRAS signaling; (c) epithelial mesenchymal transition; (d) colorectal cancer MYC; (e) primary immunodeficiency syndrome; (f) cell cycle G1 S. CRC: colorectal cancer.
Figure 5. The relationship between LINC01121 expression and immune cell infiltration.
Figure 6. LINC01121 mediates the proliferation, migration, and invasion of DLD1 cells. (a) The expression level of LINC01121 in CRC tissue and adjacent tissues. (b) RT-qPCR was used to access the expression level of LINC01121 in DLD1 after knockdown. (c-e) CCK8 and EdU assays assessed the cell proliferation levels after LINC01121 knockdown. (f, g) Scratch assays were performed to detect the cell migration ability after LINC01121 knockdown. (h, i) Transwell invasion assays showed the cell invasion ability after LINC01121 knockdown. (j) Western blotting revealed the change of E-cadherin and N-cadherin expression after LINC01121 knockdown. Data are represented as mean ± SD. P values were calculated via one-way ANOVA test. **P < 0.01, ***P < 0.001, ****P < 0.0001. ANOVA: analysis of variance; CRC: colorectal cancer; RT-qPCR: reverse transcription-quantitative polymerase chain reaction.
Table
Table 1. Clinical Information of Colorectal Patients in TCGA
| Characteristics | Low expression of LINC01121 | High expression of LINC01121 | P value |
|---|
| TCGA: The Cancer Genome Atlas. |
| n | 322 | 322 | |
| Gender, n (%) | | | 0.693 |
| Male | 169 (26.2%) | 174 (27%) | |
| Female | 153 (23.8%) | 148 (23%) | |
| Age, n (%) | | | 0.152 |
| ≤ 65 | 129 (20%) | 147 (22.8%) | |
| > 65 | 193 (30%) | 175 (27.2%) | |
| Pathologic T stage, n (%) | | | 0.118 |
| T1 | 15 (2.3%) | 5 (0.8%) | |
| T2 | 56 (8.7%) | 55 (8.6%) | |
| T3 | 217 (33.9%) | 219 (34.2%) | |
| T4 | 33 (5.1%) | 41 (6.4%) | |
| Pathologic N stage, n (%) | | | 0.568 |
| N0 | 190 (29.7%) | 178 (27.8%) | |
| N1 | 75 (11.7%) | 78 (12.2%) | |
| N2 | 55 (8.6%) | 64 (10%) | |
| Pathologic M stage, n (%) | | | 0.191 |
| M0 | 244 (43.3%) | 231 (41%) | |
| M1 | 39 (6.9%) | 50 (8.9%) | |
| Pathologic stage, n (%) | | | 0.545 |
| Stage I | 58 (9.3%) | 53 (8.5%) | |
| Stage II | 125 (20.1%) | 113 (18.1%) | |
| Stage III | 89 (14.3%) | 95 (15.2%) | |
| Stage IV | 40 (6.4%) | 50 (8%) | |